Home / Market News / $ADAG

$ADAG news and market catalysts

The 8 most recent market catalysts affecting $ADAG, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

8 catalysts 1 high impact 4 bullish 1 bearish Biotechnology
Nov 18, 2026 Corporate Catalyst Bullish Impact 65
Adagene and City of Hope Launch Phase 1 Clinical Trial for Metastatic Colorectal Cancer Combination Therapy
Adagene Inc. and City of Hope announced the launch of a Phase 1 clinical trial for a combination therapy involving ivonescimab, Adagene's muzastotug (ADG126), and chemotherapy for …
Nov 10, 2026 Corporate Catalyst Bullish Impact 65
Adagene Announces Completion of Enrollment in Phase 2 Trial of Muzastotug
Adagene Inc. has completed enrollment in its Phase 2 trial for muzastotug, an anti-CTLA-4 SAFEbody®, in combination with Merck's KEYTRUDA for late-line MSS colorectal cancer. This …
Nov 9, 2026 Corporate Catalyst Bullish Impact 65
Sanofi Makes Additional Equity Investment in Adagene Trial
Adagene Inc. (ADAG) has received an additional equity investment from Sanofi (SNY) to support the clinical trial of muzastotug, a drug candidate for solid tumors. This funding is a…
Nov 9, 2026 Corporate Catalyst Bullish Impact 55
Adagene Completes Enrollment in Phase 2 Trial of Muzastotug with Merck's KEYTRUDA
Adagene Inc. has completed patient enrollment for its Phase 2 trial of muzastotug (ADG126) in combination with Merck's KEYTRUDA. This is a significant operational milestone in drug…
Oct 19, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $7 Price Target
HC Wainwright & Co. analyst Arthur He reiterated a 'Buy' rating and maintained a $7 price target for Adagene. This action signals continued analyst confidence in Adagene's future p…
Sep 22, 2026 Corporate Catalyst Neutral Impact 65
China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology
Adagene announced the NMPA approval of its IND application for ADG138, a double-masked HER2×CD3 bispecific T cell engager. This approval is a crucial regulatory milestone, allowing…
Sep 10, 2026 Corporate Catalyst Neutral Impact 65
Chardan Capital Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
Chardan Capital's initiation of coverage on Adagene with a 'Buy' rating and a $9 price target is a positive development for the company. Analyst coverage often brings increased inv…
Aug 12, 2026 Corporate Catalyst Bearish Impact 95
Adagene H1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $1.620M
Adagene reported H1 adjusted EPS of $(0.20), missing analyst estimates of $(0.10) by a substantial 100%. This is a significant negative surprise for investors, indicating worse-tha…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.